GlobeNewswire

Cisco Releases New Developer Capabilities Across Its Intent-Based Networking Platform

Dela

ORLANDO, Fla., June 12, 2018 (GLOBE NEWSWIRE) -- CISCO LIVE - Cisco today announced that it has released new developer capabilities across its intent-based networking platform. These advancements underscore Cisco's continued progress in delivering an open, programmable platform that spans the entire network, from campus to data center, branch to edge. By providing an open network, Cisco is empowering 500,000 developers, 60,000 partners and three million network engineers to innovate upon the platform.

Intent-based networking represents a fundamental shift in the way networks are built and managed. Moving away from the manual, time-intensive methods by which networks are traditionally managed, these modern networks capture business intent and translate it into network policies. These policies are then automatically activated across the entire infrastructure, with the assurance that the business intent was delivered as planned.

"Intent-based networking represents the next generation of open, IP-based systems that we've seen can change the actual fabric of society," said David Goeckeler, executive vice president and general manager of Cisco's Networking and Security Business. "Cisco is building an open architecture that will power an ecosystem to accelerate intent-based networking innovation. Already, our customers and partners are creating value from their networks in ways they thought weren't possible as recently as one year ago."

Announcing the DNA Center platform 
Today, Cisco is releasing new developer tools and open APIs into Cisco DNA(TM) Center - the command and control center for campus, branch and edge intent-based networks. DNA Center turns the network from a combination of hardware devices into a single system. With the availability of network-wide APIs, Cisco now allows developers to easily program this system, tapping into all of the analytics and insight the network can provide.

With a rich API catalog, DNA Center allows customers to protect and inform their business like never before.

Elevating network intelligence into business operations: DNA Center helps enable developers to program the network as a single system through intent-based APIs. Now, developers can more easily create a new generation of network-aware applications, and partners can integrate the network into business processes.

Streamline IT processes across functions: DNA Center helps enable network IT administrators to exchange information to automate processes across IT systems through software adapters. Now, IT can move resources from operation to innovation.

Managing multi-vendor networks: DNA Center gives developers and partners the flexibility to support multi-vendor networks via a software developer kit (SDK). This allows customers to simplify the complexity of heterogeneous networks and manage them consistently, as a single system. 

Already, 15 Cisco partners have built innovative solutions on the DNA Center platform and are demonstrating them at Cisco Live. 

Announcing the largest developer community for intent-based networking 
Cisco is also announcing that its developer community, DevNet, has surpassed 500,000 members. In building this large and active community, Cisco has introduced a new source of innovation as the network becomes increasingly programmable.

Today, Cisco is announcing three new developer initiatives to fuel its innovation ecosystem:

  • DevNet Ecosystem Exchange makes it easy to find and share an application or solution built for Cisco platforms. Business leaders and developers alike can use this online portal to discover partner solutions that span all Cisco platforms and products. It contains over 1,300 solutions.

  • DevNet Code Exchange gives developers a place to access and share software to quickly build next-generation applications and workflow integrations. A curated list of sample code, adaptors, tools, and SDKs is available on GitHub and written by Cisco and the DevNet community. Code Exchange spans Cisco's entire portfolio and is organized according to Cisco platform and product areas.

  • DevNet DNA Developer Center is a one-stop-shop for developers to build applications and integrations on the DNA Center platform. It provides comprehensive resources, capabilities, use cases and learning materials for developers.

Availability, Services and Support

  • The new DNA Center capabilities are scheduled to be available during the summer of 2018. Customers can purchase these new capabilities from Cisco and its partners via existing subscription offers.

  • DevNet's Ecosystem Exchange, Code Exchange, and DNA Developer Center are available now.

  • Cisco and its partners offer a full lifecycle of services to help customers streamline the journey to truly intent-based networks.

Additional Information

About Cisco
Cisco (NASDAQ:CSCO) is the worldwide technology leader that has been making the Internet work since 1984. Our people, products, and partners help society securely connect and seize tomorrow's digital opportunity today. Discover more at newsroom.cisco.com and follow us on Twitter at @Cisco.

Cisco, the Cisco logo, Cisco and Cisco IOS Systems are registered trademarks or trademarks of Cisco Systems, Inc. and/or its affiliates in the United States and certain other countries. All other trademarks mentioned in this document are the property of their respective owners. The use of the word partner does not imply a partnership relationship between Cisco and any other company. This document is Cisco Public Information.

Press Relations: 
Gareth Pettigrew
+1-250-240-0638
gpettigr@cisco.com

RSS Feed for Cisco: http://newsroom.cisco.com/rss-feeds




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cisco via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development delays publication of its Annual Report for 2018 and changes date for the Annual General Meeting26.4.2019 08:00:00 CESTPressmeddelande

STOCKHOLM, SWEDEN - 26 April 2019. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that The Board of Directors has decided to delay the publication of its Annual Report for 2018. Karolinska Development has changed the date for the Annual General Meeting to June 26, 2019. The date for publication of the Annual Report for 2018 has been changed from April 26 to April 30, 2019. Karolinska Development has changed the date for the Annual General Meeting from June 4 to June 26, 2019. Notice to the Annual General Meeting will be published in a separate press release. For more information, please contact: Viktor Drvota, CEO, Karolinska Development AB Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com Fredrik Järrsten, CFO, Karolinska Development AB Phone: +46 70 496 46 28, e-mail: fredrik.jarrsten@karolinskadevelopment.com TO THE EDITORS About Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investmen

Karolinska Development senarelägger publicering av årsredovisningen för 2018 och meddelar nytt datum för årsstämma26.4.2019 08:00:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 26 april 2019. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att styrelsen har beslutat att senarelägga publiceringen av årsredovisningen för 2018. Karolinska Development har ändrat datum för årsstämman till den 26 juni 2019. Publiceringen av årsredovisningen för 2018 flyttas från den 26 april till den 30 april 2019. Karolinska Development har ändrat datum för årsstämman från den 4 juni till den 26 juni 2019. Kallelse till årsstämman kommer att publiceras senare i ett separat pressmeddelande. För ytterligare information, vänligen kontakta: Viktor Drvota, vd, Karolinska Development AB Tel: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com Fredrik Järrsten, finanschef, Karolinska Development AB Tel: +46 70 496 46 28, e-mail: fredrik.jarrsten@karolinskadevelopment.com TILL REDAKTÖRERNA Om Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) är ett nordiskt investmentbolag inom life science. Bolaget fokuserar p

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum